[PDF] Top 20 Cambios Fisiológicos en el hombre y la mujer
Has 10000 "Cambios Fisiológicos en el hombre y la mujer" found on our website. Below are the top 20 most common "Cambios Fisiológicos en el hombre y la mujer".
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
... of pirfenidone is 801 mg three times per day (2403 mg·day −1 ) with a 14-day titration period upon treatment initiation (table 2) ...of pirfenidone-related ...better pirfenidone tolerability (table ... See full document
23
Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
... that pirfenidone significantly slows disease progression and reduces mortality in patients with IPF [3, ...use, pirfenidone has been shown to have a favourable safety profile and was generally well ... See full document
94
<p>Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis</p>
... in FVC in IPF patients as compared to the placebo group in both, INPULSIS I ( − 114.7 mL vs − 239.9 mL, p <0.001) and INPULSIS II ( − 113.6 mL VS − 207.3 mL, p<0.001) over 52 weeks. 7 The most common side effect of ... See full document
5
Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
... against pirfenidone the company performed an indirect treatment comparison using Bayesian random effects network meta-analysis ...key adverse event ...for pirfenidone were broadly similar to ... See full document
25
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
... of safety out- comes in a large and well-de fi ned cohort of patients with IPF who were treated with pirfenidone and followed prospectively for up to ...with pirfenidone is safe and gener- ally well ... See full document
196
The therapy of idiopathic pulmonary fibrosis: what is next?
... the management of comorbidities that can influence cough, such as gastro-oesophageal reflux disease (GORD) ...the safety and efficacy of opioids for the management of cough in the terminal stages and ... See full document
71
Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy
... long-term safety profile of ...of pirfenidone with a median exposure of ...common adverse drug reactions observed have been gastrointestinal symptoms (nausea, decreased appetite, weight loss) and ... See full document
9
Clinical course and management of idiopathic pulmonary fibrosis
... lung fibrosis suggest that nintedanib and pirfenidone inhibit processes that are fundamental to the progression of fibrosis such as the proliferation, migration and differentiation of fibroblasts and ... See full document
7
Pirfenidone treatment of idiopathic pulmonary fibrosis
... Abstract: Idiopathic pulmonary fibrosis (IPF) is a discrete clinicopathologic entity defined by the presence of usual interstitial pneumonia on high-resolution CT scan and/or open lung biopsy and the ... See full document
19
Update on therapeutic management of idiopathic pulmonary fibrosis
... Gastrointestinal adverse events, including nausea, dyspepsia, anorexia, and gastroesophageal reflux, were more common in the pirfenidone group than in the placebo group ...Skin-related adverse events ... See full document
5
Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
... Abstract: Idiopathic pulmonary fibrosis (IPF) is a devastating chronic fibrotic lung ...of pulmonary fibrosis involves multiple mechanisms, with abnormal behavior of alveolar epithelial ... See full document
44
Management of idiopathic pulmonary fibrosis: selected case reports
... a pulmonary infection. Pulmonary function tests (PFTs) showed only mild impairment of vital capacity (VC) but a severely reduced diffusing capacity of the lung for carbon monoxide (D LCO ...diffuse ... See full document
7
Development and utility of pirfenidone in the treatment of idiopathic pulmonary fibrosis: review of preclinical science and recent clinical trials
... Idiopathic pulmonary fibrosis (IPF), a fatal fibrosing lung disease occurring pre- dominantly in older men, has been the most prominent target in clinical ...of pirfenidone in several disease ... See full document
8
Idiopathic pulmonary fibrosis
... Since the mid-1990s, attention has focused on the divi- sion of idiopathic pulmonary fibrosis into histologically- defined subgroups. This practice stems from the descrip- tion of NSIP in 1994 [79]. ... See full document
5
Original Article Identification of key genes associated with idiopathic pulmonary fibrosis using bioinformatics analysis
... Functional enrichment indicated that LTBP3 was involved in extracellular matrix organiza- tion. The ECM protein LTBP3 have a dual func- tion, which is required both for the secretion of small latent TGF-beta complex and ... See full document
143
Epidemiology of idiopathic pulmonary fibrosis
... Abstract: Idiopathic pulmonary fibrosis is a chronic fibrotic lung disease of unknown cause that occurs in adults and has a poor prognosis. Its epidemiology has been difficult to study because of its ... See full document
12
Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines
... [59], pirfenidone (1800 mg?day -1 ) significantly reduced FVC decline compared to ...NCT01366209). Pirfenidone was granted European marketing authorisation in 2011, and was marketed in France in 2012 for ... See full document
7
Combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis in non-small cell lung cancer: impact on survival and acute exacerbation
... concomitant idiopathic pulmonary fibrosis (IPF) and emphysema (CPFE) are independently related to poor ...both pulmonary fibrosis and ... See full document
10
Cough in idiopathic pulmonary fibrosis
... Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease of unknown cause with a median survival of 3 – 5 years after diagnosis [1]. Treatment of IPF aims at slowing or stopping the disease ... See full document
33
Review Article IPF and lung cancer: homologous but different endings, the progress in the correlation research
... cystic fibrosis, asthma, lung cancer, COPD (chronic obstructive pulmonary disease) and IPF is well- documented ...of pulmonary fibrosis ...the event of its downregulation ... See full document
162
Related subjects